Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 121Lung Neoplasms 49Triple Negative Breast Neoplasms 35Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 24Ovarian Neoplasms 24Neoplasm Metastasis 21Fallopian Tube Neoplasms 19Endometrial Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 15Head and Neck Neoplasms 12Colorectal Neoplasms 11Carcinoma 10Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Mouth Neoplasms 5Mesothelioma 5Lung Diseases 5Laryngeal Neoplasms 5Respiratory Tract Neoplasms 4

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Carboplatin × 90 days × Clear all
NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
20 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡